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Abstract 
KX2-391 (KX-01/Kinex Pharmaceuticals), N-benzyl-2-(5-(4-(2-
morpholinoethoxy)phenyl)pyridin-2-yl)acetamide, is a highly selective Src substrate 
binding site inhibitor. To understand better the role of pyridine ring and N-
benzylsubstitution in KX2-391 and establish the structure-activity relationship, a number 
of N-benzyl substituted (2-morpholinoethoxy)phenyl)thiazol-4-yl)acetamide derivatives 
containing thiazole instead of pyridine were synthesized and evaluated for Src kinase 
inhibitory activities. The unsubstituted N-benzyl derivative (8a) showed the inhibition of 
c-Src kinase with GI50 values of 1.34 µM and 2.30 µM in NIH3T3/c-Src527F and SYF/c-
Src527F cells, respectively. All the synthesized compounds were evaluated for inhibition 
of cell proliferation of human colon carcinoma (HT-29), breast carcinoma (BT-20), and 
leukemia (CCRF-CEM) cells. 4-Fluorobenzylthiazolyl derivative 8b exhibited 64-71% 
inhibition in the cell proliferation of BT-20 and CCR5 cells at concentration of 50 µM. 
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1. Introduction 
Src is the prototype and most widely studied member of one of the largest family of 
non-receptor protein tyrosine kinases (PTKs), known as the Src family kinases (SFKs) 
[1], which are key regulators of cellular proliferation, survival, motility and invasiveness 
[2-4]. Src was first discovered in viral sarcoma and thus was pronounced as “sarc”. Src 
offers a promising molecular target for anticancer therapy, as increased Src activity 
upregulates a number of signaling cascades associated with tumor development and 
progression leading to increased cell growth, migration and invasion. Moreover, Src has 
been shown to play a critical role in other pathologic disorders, such as myocardial 
infarction [5], stroke [6], osteoporosis [7], and neurodegeneration [1].  
In the last two decades, synthesis of Src kinase inhibitors has been based on 
designing ATP binding site inhibitors and substrate binding site inhibitors. Despite of the 
large variety in PTKs structural organization, their ATP binding site is mostly conserved. 
The ATP binding site competitive inhibitors of Src that mimic the binding of ATP are 
potent, but often lack selectivity in a panel of isolated kinase assays [8-10]. In contrary, 
the substrate binding site sequences of PTKs are less conserved, which results in 
improved selectivity and less toxicity of designed substrate binding site inhibitors when 
compared with those of ATP mimics targeting ATP binding site. 
KX2-391 (KX-01/Kinex Pharmaceuticals) (Fig. 1) is a novel class and highly 
selective non-ATP Src kinase inhibitor that targets the substrate binding site of Src, has 
tubulin polymerization inhibition as a second mechanism of action, and is currently in 
Phase-2 testing for solid tumors [11]. KX2-391 was found to inhibit certain leukemia 
cells that are resistant to current commercially available drugs, such as those derived 
from chronic leukemia cells with the T3151 mutation. In pre-clinical animal models of 
cancer, orally administered KX2-391 was shown to inhibit primary tumor growth and to 
suppress metastasis. In combination with certain chemotherapeutic agents, KX2-391 
was synergistic, thereby, offering the potential to prescribe lower doses of some current 
cytotoxic agents that have undesirable side effects. 
 
Please insert Figure 1 here. 
 
In addition, previous structural studies [12-14] have proven that occurrence of 
heterocyclic scaffolds such as thiazole may result in generating effective kinase 
inhibitors, including potent Src kinase inhibitors. Dasatinib (Fig. 1) with amino-thiazole 
moiety, is one of the potent pan-Src kinase inhibitors, which has been approved by FDA 
for the treatment of Gleevec-resistant CML [15,16]. 
Since the crystal structure of substrate binding site with Src inhibitors is not 
available yet, the designing strategy for discovering selective Src substrate binding site 
inhibitors has been mostly based on screening rather than rational designing [17]. 
Considering these facts, and in continuation of our efforts to design small molecules as 
Src kinase inhibitor or anticancer agents [18], we herein report the synthesis a series of 
substrate binding site inhibitors by substituting pyridine ring in KX2-391 molecule with a 
thiazole group and introducing substitutions on the benzyl ring. Src kinase inhibitory and 
anticancer activities of the compounds were evaluated  in cell-based assays.  
 2. Results and discussions 
2.1. Chemistry 
Scheme 1 outlines the procedure for the synthesis of thiazolyl benzyl acetamides 
8a−e. Commercially available 4-(2-chloroethyl)morpholine hydrochloride (1) was 
reacted with 4-hydroxybenzonitrile (2) in presence of K2CO3 in refluxing DMF for 24 h to 
yield 4-(2-morpholinoethoxy)benzonitrile (3). Subsequent reaction of 3 with ammonium 
sulfide at room temperature afforded 4-(2-morpholinoethoxy)benzothioamide 4. 
Treatment of 4 with ethyl 4-chloroacetoacetate resulted in the formation of thiazolyl 
derivative 5, which underwent basic ester hydrolysis to generate acetic acid derivative 
6. Finally, the reaction of 6 with the corresponding benzylamines 7a−e in the presence 
of 1-hydroxybenzotriazole (HOBt) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide 
hydrochloride (EDCI) in acetonitrile afforded desired thiazolyl benzyl acetamides 8a−e. 
 
Please insert Scheme 1 here. 
 
2.2. Biological Activity 
2.2.1. Src Kinase Inhibitory Activity 
The compounds were evaluated in engineered Src driven cell growth assays in 
NIH3T3/c-Src527F and SYF/c-Src527F cells. NIH3T3/c-Src527F cell line has 
constitutively active human Src driving growth. SYF/c-Src527F has Src, Yes, and Fyn 
mouse knockouts with cSrc527F added back. The results of Src kinase inhibitory 
activity of compounds 8a−e are shown in Table 1 and Fig. 2. Compound 8a with no 
substitution on N-benzyl group showed GI50 values of 1.34 µM and 2.30 µM in 
NIH3T3/c-Src527F and SYF/c-Src527F cells, respectively, and was found to be the 
most potent compound of this series. Introducing of a fluoro group at position 4 of 
benzyl group led to a slight decrease of inhibitory activity in compound 8b (GI50 = 
1.49−2.51 µM) versus 8a. Introducing of a methyl group at position 4 of benzyl group in 
8e led to almost 4-fold decrease of potency in comparison with 8a. Similarly 2-
chlorobenzyl and 3,4-dichlorobenzyl substituted analogs (8c and 8d) showed 
significantly less inhibitory activities when compared to other compounds (GI50 
=7.93−13.02 µM). The data suggest that incorporation of bulky groups, such as chlorine 
and methyl in compounds 8c−e with higher lipophilicity (Log P), results in decreased 
potency.  
All the tested compounds were significantly less potent than KX2-391, suggesting 
that introducing thiazole replacement of pyridine has led to decreased activity. In other 
words, pyridine is possibly a pharmacophore of KX2-391 that has major interactions 
with Src substrate binding site. Nevertheless, none of the compounds were active in 
vitro assay against Src Kinase, which confirm earlier results that the peptide binding site 
is not well formed outside of cells and these compounds indeed inhibit Src in cellular 
environment when the substrate binding site is deeper for binding interactions.  
Please insert Table 1 here. 
 Please insert Figure 2 here. 
 
2.2.2. Anticancer Activities 
The effect of the inhibitors at the concentration of 50 µM on the cell proliferation of 
human colon adenocarcinoma (HT-29) cancer cells that overexpress c-Src [19], breast 
carcinoma (BT-20), and leukemia (CCRF-CEM) cells was also evaluated (Fig. 3). In 
general, compounds 8a and 8c showed moderate activity against CCR5 and BT-20 
compared to doxorubicin (DOX) by inhibiting the cell proliferation by 30-40%. On the 
other hand, compounds 8b, 8d, and 8e inhibited the cell proliferation of CCR5 and BT-
20 by 61-71%, and HT-29 by 54-56%(Fig. 3).  
Structure−activity relationship studies suggest that the presence of substituents at 
position 4 of benzyl ring (4-fluoro-, 3,4-dicholor, or 4-methyl) is critical for maximum 
anticancer activity as seen in compounds 8b, 8c, or 8e. Compound 8b that showed high 
Src inhibitory potency against Src was consistently also active against all cancer cells. 
On the other hand, poor correlation was observed between Src kinase inhibitory 
potency and the inhibition of cell proliferation in cancer cells for other compounds. For 
example, while compound 8a that was one of the most potent Src kinase inhibitors in 
this class, showed much weaker anticancer activities versus other compounds. Thus, 
some other mechanisms may be involved rather than Src kinase inhibition in generating 
anticancer activity. 
Compounds 8b−e have slightly higher lipophilicity than 8a as shown in Log P 
values. As can be seen in Fig. 3, after 72 h compounds 8b−e exhibited significantly 
higher cell proliferation inhibitory activity when compared to that of 24 h in colon cancer 
cells HT-29. These data suggest that other factors like lipid solubility and cellular uptake 
may also contribute in anticancer activities of these compounds. 
 
Please insert Figure 3 here. 
 
3. Conclusions 
In summary, a number of N-benzyl substituted (2-morpholinoethoxy)phenyl)thiazol-
4-yl)acetamide were prepared and evaluated for Src kinase inhibitory and anti cancer 
activities. Although the biological results revealed that introducing thiazole replacement 
of pyridine in KX2-391 led to decreased activity, the compounds retained Src kinase 
inhibitory activities at low micomolar range (1.34-13.02 µM) in NIH3T3/c-Src527F and 
SYF/c-Src527F cells. Structure−activity relationship studies revealed that the presence 
of a substituent at position 4 of benzyl ring (4-fluoro-, 3,4-dicholor, or 4-methyl) is critical 
for maximum anticancer activity. For example, 4-fluorosubstituted (8b) and 3,4-
dichlorosubsitited (8d) analogs inhibited the cell proliferation of CCR5 by 71% and 69%, 
respectively (Fig. 3). This study provides insights and structure-activity relationships for 
further optimization of this scaffold for generating optimal Src inhibitory and anticancer 
activities. 
 5. Experimental protocols 
5.1. Materials and methods 
All starting materials, reagents, and solvents were purchased from Merck AG 
(Germany). The purity of the synthesized compounds was confirmed by thin layer 
chromatography (TLC) using various solvents of different polarities. Merck silica gel 60 
F254 plates were applied for analytical TLC. Column chromatography was performed 
on Merck silica gel (70–230 mesh) for purification of the intermediate and final 
compounds. Melting points were determined on a Kofler hot stage apparatus (Vienna, 
Austria) and are uncorrected. 1H NMR spectra were recorded using a Bruker 500 MHz 
spectrometer (Bruker, Rheinstatten, Germany), and chemical shifts are expressed as δ 
(ppm) with tetramethylsilane (TMS) as an internal standard. Proton coupling patterns 
are described as singlet (s), doublet (d), triplet (t), quartet (q), multiplet (m), and broad 
(br). The IR spectra were obtained on a Shimadzu 470 (Shimadzu, Tokyo, Japan) 
spectrophotometer (potassium bromide disks). The mass spectra were run on a 
Finnigan TSQ-70 spectrometer (Finnigan, USA) at 70 eV. Elemental analyses were 
carried out on a CHN-O-rapid elemental analyzer (Heraeus GmbH, Hanau, Germany) 
for C, H, and N, and the results were within ± 0.4% of the theoretical values. 
 
 
 
5.2. Chemistry 
5.2.1. 4-(2-Morpholinoethoxy)benzonitrile (3). A mixture of 4-(2-
chloroethyl)morpholine hydrochloride 1 (9.5 g, 0.05 mol), 4-hydroxybenzonitrile 2 (6 g, 
0.05 mol) and K2CO3 (17.3 g, 0.13 mol) in anhydrous DMF (150 mL) was refluxed for 24 
h. After cooling the reaction mixture to room temperature, it was poured in to cold 
water(100 mL) with crushed ice (100 mL) and the resulted light brown precipitate was 
collected and dried to obtain pure 3 in 76% yield. IR (KBr): ν = 2217(CN). 1H 
NMR(CDCl3): δ 7.59(d, J = 9 Hz, 2H,-ArH), 6.96(d, J = 9 Hz, 2H, -ArH), 4.16 (t, J = 11.5 
Hz, 2H, -CH2), 3.74 (t, J = 9 Hz, 4H, -CH2), 2.83 (t, J = 11.5 Hz, 2H, -CH2), 2.58 (t, J = 9 
Hz, 4H, -CH2). MS m/z (%): 232 [M]+ (45), 114 (12.5), 100 (100), 70 (25), 56 (48), 42 
(36). 
 
5.2.2. 4-(2-Morpholinoethoxy)benzothioamide (4). Ammonium sulfide (23 mL, 0.068 
mol) was added slowly to a stirring mixture of 3 (8 g, 0.034 mol) in DMF (45 mL) at room 
temperature. The mixture was stirred at the same temperature overnight and then was 
poured in to crushed ice (150 mL). The yellow precipitate was collected and dried to 
give pure 4 in 71% yield. IR (KBr): ν = 3370,3155(NH2), 1654(C=S). 1H NMR (CDCl3): δ 
7.90 (d, J = 9 Hz, 2H,-ArH), 7.58 (br, 1H, -NH2), 7.16 (br, 1H, -NH2), 6.91 (d, J = 9 Hz, 
2H, -ArH), 4.16 (t, J = 11.5 Hz, 2H, -CH2), 3.74 (t, J = 9 Hz, 4H, -CH2), 2.83 (t, J = 11 
Hz, 2H, -CH2), 2.59 (t, J = 9 Hz, 4H, -CH2). MS m/z (%): 266 [M]+ (88), 114 (12), 100 
(100), 70 (16), 56 (32), 42 (20). 
5.2.3. Ethyl 2-(2-(4-(2-morpholinoethoxy)phenyl)thiazol-4-yl)acetate (5). To a 
mixture of 4 (6 g, 0.022 mol) in ethanol (60 mL), ethyl 4-chloroacetoacetate (3.5 mL, 
0.025 mol) and a few drops of pyridine were added. The reaction mixture was then 
refluxed for 4 h. After cooling to ambient temperature, the solvent was evaporated and 
the oily residue was purified by flash column chromatography (CH3COOC2H5/n-C6H14) 
to give pure brownish oil of 5 in 54% yield. 1H NMR (CDCl3): δ 7.87(d, J = 9 Hz, 2H,-
ArH), 7.46 (s, 1H, -CH-thiazole), 7.11 (d, J = 9 Hz, 2H, -ArH), 4.11 (m, 4H, -CH2), 3.92 
(t, J = 11 Hz, 4H, -CH2), 3.85 (s, 2H, -CH2), 2.82 (t, J = 11 Hz, 2H, -CH2), 2.58 (t, J = 9 
Hz, 4H, -CH2), 1.28 (t, J = 10 Hz, 3H, -CH3). MS m/z (%): 376 [M]+ (8), 121 (100), 105 
(72), 77 (36), 57 (24), 43 (28). 
5.2.4. 2-(2-(4-(2-Morpholinoethoxy)phenyl)thiazol-4-yl)acetic acid (6). Sodium 
hydroxide solution (30 mL, 1 N) was added to a mixture of 5 (4 g, 0.01 mol) in ethanol 
(20 mL) and was refluxed overnight. The mixture was then cooled to ambient 
temperature and neutralized with HCl. The remaining solvent was evaporated and the 
oily residue was purified by flash column chromatography (CH3OH/CH3COOC2H5) to 
give 6 in 42% yield. IR (KBr): ν = 3431 (OH), 1710 (C=O). 1H NMR (DMSO-d6): δ 
7.83(d, J = 8.8 Hz, 2H,-ArH), 7.40 (s, 1H, -CH-thiazole), 7.04 (d, J = 8.8 Hz, 2H, -ArH), 
4.15 (t, J = 11.45 Hz, 4H, -CH2), 3.75 (s, 2H, -CH2), 3.58 (t, J = 9 Hz, 4H, -CH2), 2.71 (t, 
J = 11.45 Hz, 2H, -CH2), 2.50 (t, J = 9 Hz, 4H, -CH2). MS m/z (%): 348 [M]+ (28), 114 
(64), 100 (100), 71 (20), 56 (28), 42 (16). 
5.2.5. N-Benzyl-2-(2-(4-(2-morpholinoethoxy)phenyl)thiazol-4-yl)acetamide (8a). A 
mixture of acid 6 (0.5 g, 1 mmol), EDCI (0.21 g, 1.1 mmol), and HOBt (0.15 g, 1 mmol) 
in dry CH3CN (10 mL) was stirred at room temperature for 30 min and then treated with 
the benzyl amine 7a (0.11 mL, 1 mmol). The mixture was stirred at room temperature 
for an additional 24 h. Then the solution was evaporated to dryness in vacuum. The 
residue was dissolved in ethyl acetate (20 mL) and washed sequentially with brine (2 × 
5 mL), 10% aqueous sodium carbonate (2 × 5 mL), 10% aqueous citric acid (2 × 5 mL), 
and water (2 × 5 mL). The organic layer was dried over anhydrous sodium sulfate. 
Concentration of the dried extract yielded an oily residue, which was crystallized 
(CH2Cl2/ n-C6H14) to give pure 8a amide in 27% yield. M.P. 104-108 °C; 1H NMR 
(CDCl3): δ 7.74 (d, J = 8.9 Hz, 2H, -ArH), 7.41 (br, 1H, -NH), 7.28 (m, 5H, -ArH), 7.03 (s, 
1H, -CH-thiazole), 6.91(d, J = 8.9 Hz, 2H, -ArH), 4.48 (d, J = 5.5 Hz, 2H, -CH2), 4.24 (m, 
2H, -CH2), 3.81(m, 4H, -CH2), 3.78 (s, 2H, -CH2), 2.93 (m, 2H, -CH2), 2.71 (m, 4H, -
CH2); 13C NMR (CDCl3): δ 39.09, 43.67, 53.93, 57.41, 65.58, 66.49, 114.88, 115.05, 
126.42, 127.32, 127.54, 127.92, 128.64, 138.17, 150.40, 160.19, 168.52, 169.04; MS 
m/z (%): 437 [M]+ (12), 114 (72) , 100 (100). Anal. calcd. for C24H27N3O3S: C, 65.88; H, 
6.22; N, 9.60; found: C, 65.46; H, 5.98; N, 9.79. 
5.2.6. N-(4-Fluorobenzyl)-2-(2-(4-(2-morpholinoethoxy)phenyl)thiazol-4-
yl)acetamide (8b). The same procedure described for 8a was used starting with 4-
fluorobenzylamine 7b, Yield 23%. M.P. 148-151°C; 1H NMR (CDCl3): δ 7.73 (d, J = 8.8 
Hz, 2H,-ArH), 7.42 (br, 1H, -NH), 7.23 (m, 2H, -ArH), 7.02 (s, 1H, -CH-thiazole), 6.97(t, 
J = 17.4 Hz, 2H, -ArH), 6.91(d, J = 8.8 Hz, 2H, -ArH), 4.43 (d, J = 5.5 Hz, 2H, -CH2), 
4.21 (m, 2H, -CH2), 3.77 (m, 5H, -CH2), 2.89 (m, 2H, -CH2), 2.66 (m, 4H, -CH2); 13C 
NMR (CDCl3): δ 39.05, 42.95, 53.99, 57.44, 65.75, 66.65, 114.89, 115.06, 115.36, 
115.53, 126.26, 127.85, 129.21, 129.27, 134.02, 150.28, 160.33, 161.08, 168.57, 
169.04; MS m/z (%): 455 [M]+ (32), 114 (76), 100 (100). Anal. calcd. for C24H26FN3O3S: 
C, 63.28; H, 5.75; N, 9.22; found: C, 63.87; H, 6.02; N, 9.53. 
5.2.7. N-(2-Chlorobenzyl)-2-(2-(4-(2-morpholinoethoxy)phenyl)thiazol-4-
yl)acetamide (8c). The same procedure described for 8a was used starting with 2-
chlorobenzylamine 7c, Yield 21%. M.P. 114-116 °C; 1H NMR (CDCl3 ): δ 7.81(d, J = 9 
Hz, 2H, -ArH), 7.65 (br, 1H, -NH), 7.37 (m, 1H, -ArH), 7.33 (m, 1H, -ArH), 7.19 (m, 2H, -
ArH), 7.00 (s, 1H, -CH-thiazole), 6.93 (d, J = 8.8 Hz, 2H, -ArH), 4.56 (d, J = 6 Hz, 2H, -
CH2), 4.17 (t, J = 11 Hz,  2H, -CH2), 3.75 (m, 5H, -CH2), 2.84 (t, J = 10 Hz, 2H, -CH2), 
2.60 (m, 4H, -CH2); 13C NMR (CDCl3): δ 39.03, 41.47, 54.00, 57.45, 65.76, 66.70, 
114.84, 114.97, 126.27, 127.00, 127.90, 128.71, 129.39, 129.83, 133.57, 135.72, 
150.26, 160.31, 168.62, 169.03; MS m/z (%): 473 [M+2]+ (8), 471 [M]+ (16), 114 
(76),100 (100). Anal. calcd. for C24H26ClN3O3S: C, 61.07; H, 5.55; N, 8.90; found: C, 
60.87; H, 5.89; N, 8.35. 
5.2.8. N-(3,4-Dichlorobenzyl)-2-(2-(4-(2-morpholinoethoxy)phenyl)thiazol-4-
yl)acetamide (8d). The same procedure described for 8a was used starting with 3,4-
dichlorobenzylamine 7d, Yield 33%. M.P. 129-131.5 °C; 1H NMR (CDCl3): δ 7.76 (d, J = 
8.8 Hz, 2H, -ArH), 7.52 (br, 1H, -NH), 7.34 (d, J = 2.6 Hz, 2H, -ArH), 7.33 (s, 1H, -ArH), 
7.10 (d, J = 10 Hz, 1H, -ArH), 7.03 (s, 1H, -CH-thiazole), 7.94 (d, J = 8.8 Hz, 2H, -ArH), 
4.42 (d, J = 5.8 Hz, 2H, -CH2), 4.18 (m, 2H, -CH2), 3.79 (s, 2H, -CH2), 3.75 (m, 4H, -
CH2), 2.84 (m, 2H, -CH2), 2.60 (m, 4H, -CH2); 13C NMR (CDCl3): δ 39.01, 42.46, 53.92, 
57.39, 65.62, 66.47, 114.98, 115.19, 126.30, 126.88, 127.89, 129.32, 130.54, 131.25, 
132.62, 138.68, 150.11, 159.72, 160.30, 168.74, 169.20; MS m/z (%): 507 [M+2] + (8), 
505 [M]+ (12), 114 (76),100 (100). Anal. calcd. for C24H25Cl2N3O3S: C, 61.43; H, 5.68; N, 
8.77; found: C, 61.98; H, 6.02; N, 8.14.  
 
5.2.9. N-(4-Methylbenzyl)-2-(2-(4-(2-morpholinoethoxy)phenyl)thiazol-4-
yl)acetamide (8e). The same procedure described for 8a was used starting with 4-
methylbenzylamine 7e, Yield 18%. M.P. 142-147 °C; 1H NMR (CDCl3): δ 7.74 (d, J = 8.7 
Hz, 2H, -ArH), 7.35 (br, 1H, -NH), 7.15 (d, J = 7.9 Hz, 2H, -ArH), 7.09 (d, J = 7.9 Hz, 2H, 
-ArH), 7.02(s, 1H, -CH-thiazole), 6.90 (d, J = 8.75 Hz, 2H, -ArH), 4.42 (d, J = 5.45 Hz, 
2H, -CH2), 4.17 (t, J = 11.2 Hz, 2H, -CH2), 3.77 (s, 2H, -CH2), 3.75 (t, J = 9.4 Hz, 4H, -
CH2), 2.85 (t, J = 11.2 Hz, 2H, -CH2), 2.61 (m, 4H, -CH2), 2.32 (s, 1H, -CH3); 13C NMR 
(CDCl3): δ 21.07, 39.08, 43.40, 54.01, 57.44, 65.81, 66.72, 114.83, 114.97, 126.31, 
127.53, 127.90, 128.71, 129.27, 135.13, 136.90, 150.40, 160.29, 168.47, 168.97; MS 
m/z (%): 451 [M]+ (12), 114 (60), 100 (100). Anal. calcd. for C25H29N3O3S: C, 66.49; H, 
6.47; N, 9.31; found: C, 67.21; H, 6.78; N, 9.03. 
 
5.3. Biological Assays  
5.3.1. MTT Assay 
NIH3T3/c-Src527F (4500 cells per well) and SYF/c-Src527F (3500 cells per well) 
were seeded in cells in 100 µL of DMEM media with 10% FBS in each well in a 96-well 
plate and were incubated overnight at 37o C with 5% CO2. Then, all the test compounds 
were diluted (5-point 2-fold serial dilution) in a separate 96-well plate to yield 10x of final 
concentrations. A volume of 10 µL of 10x dilutions was added to appropriate wells (n = 
3). T0 value (reflecting the starting number of cells upon drug treatment) of 3 wells of 
cells was determined by following steps as described below.  
SYF-c-Src527F cells were incubated for 2 days whereas NIH3T3/c-Src527F cells 
were incubated for 3 days at 37 oC with 5% CO2. A volume of 10 µL of MTT [20] 
solution (5 mg/mL in PBS) was added to each well and the mixture was incubated for 3 
h at 37 oC with 5% CO2. Then 100 µL of 20%SDS with 0.01 M HCl were added to each 
well and the mixture was incubated overnight at 37 oC. Afterwards, OD570 was 
measured using microplate reader. The percentage of cell growth was calculated 
according to cell growth percentage = (T-T0)/(C-T0) x 100% or OD value of the test well 
exposure to test drug - OD value at time zero / (OD of the control well without drug 
treatment - OD value at time zero) x 100%. Growth inhibition curves and GI50 were 
determined using GraphPad Prism 5 software. 
 
5.3.2. Cell Culture and Cell Proliferation Assay 
5.3.2.1. Cell Culture. Human colon adenocarcinoma HT-29 (ATCC no. HTB-38), breast 
carcinoma cells BT-20 (ATCC no. HTB-19), leukemia CCRF-CEM (ATCC no. CCL-119) 
were obtained from American Type Culture Collection. Cells were grown on 75 cm2 cell 
culture flasks with RPMI-16 medium for leukemia and EMEM medium for colon 
adenocarcinoma and breast carcinoma and supplemented with 10% fetal bovine serum 
(FBS), and 1% penicillin-streptomycin solution (10,000 units of penicillin and 10 mg of 
streptomycin in 0.9 % NaCl) in a humidified atmosphere of 5% CO2, 95% air at 37 ºC. 
 5.3.2.2. Cell Proliferation Assay. Cell proliferation assay of compounds was evaluated 
in HT-29, CCRF-CEM, and BT-20 cells, and was compared with that of doxorubicin 
(DOX) according to the previously reported procedure [21]. Cell proliferation assay was 
carried out using CellTiter 96 aqueous one solution cell proliferation assay kit (Promega, 
USA). Briefly, upon reaching about 75-80% confluency, 5000 cells/well were plated in 
96-well microplate in 100 µL media. After seeding for 72 h, the cells were treated with 
50 µM compound in triplicate. Doxorubicin (DOX, 10 µM) was used as the positive 
control. At the end of the sample exposure period (24-72 h), 20 µL CellTiter 96 aqueous 
solution was added. The plate was returned to the incubator for 1 h in a humidified 
atmosphere at 37 °C. The absorbance of the formazan product was measured at 490 
nm using microplate reader. The blank control was recorded by measuring the 
absorbance at 490 nm with wells containing medium mixed with CellTiter 96 aqueous 
solution but no cells. Results were expressed as the percentage of the control (without 
compound set at 100%). The percentage of cell survival was calculated as OD value of 
cells treated with test compound – OD value of culture medium/(OD value of control 
cells – OD value of culture medium) × 100%. 
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